Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 15, 2023

SELL
$3.38 - $4.22 $1.26 Million - $1.57 Million
-372,523 Reduced 27.57%
978,695 $3.57 Million
Q3 2022

Nov 15, 2022

SELL
$3.43 - $5.83 $1.3 Million - $2.22 Million
-380,161 Reduced 21.96%
1,351,218 $4.86 Million
Q2 2022

Aug 15, 2022

SELL
$4.41 - $5.69 $6,094 - $7,863
-1,382 Reduced 0.08%
1,731,379 $9.16 Million
Q1 2022

May 10, 2022

SELL
$4.81 - $6.99 $46,878 - $68,124
-9,746 Reduced 0.56%
1,732,761 $9.51 Million
Q4 2021

Feb 10, 2022

BUY
$5.97 - $7.93 $39,796 - $52,861
6,666 Added 0.38%
1,742,507 $11.9 Million
Q3 2021

Nov 10, 2021

SELL
$4.79 - $6.68 $196,964 - $274,681
-41,120 Reduced 2.31%
1,735,841 $10.6 Million
Q2 2021

Aug 12, 2021

BUY
$5.35 - $6.35 $3.52 Million - $4.17 Million
657,022 Added 58.67%
1,776,961 $10.5 Million
Q1 2021

May 13, 2021

BUY
$5.68 - $7.87 $2.31 Million - $3.21 Million
407,550 Added 57.21%
1,119,939 $6.73 Million
Q4 2020

Feb 16, 2021

BUY
$5.25 - $8.56 $103,146 - $168,178
19,647 Added 2.84%
712,389 $4.93 Million
Q3 2020

Nov 13, 2020

SELL
$5.78 - $7.47 $54,719 - $70,718
-9,467 Reduced 1.35%
692,742 $4.34 Million
Q2 2020

Aug 13, 2020

SELL
$4.5 - $7.02 $3.5 Million - $5.45 Million
-776,758 Reduced 52.52%
702,209 $4.64 Million
Q1 2020

May 15, 2020

BUY
$2.87 - $5.49 $229,290 - $438,607
79,892 Added 5.71%
1,478,967 $6.88 Million
Q4 2019

Feb 14, 2020

BUY
$3.84 - $4.86 $1.04 Million - $1.31 Million
270,139 Added 23.93%
1,399,075 $5.9 Million
Q3 2019

Nov 13, 2019

SELL
$4.86 - $6.05 $248,773 - $309,687
-51,188 Reduced 4.34%
1,128,936 $5.82 Million
Q2 2019

Aug 14, 2019

BUY
$4.51 - $6.6 $5.32 Million - $7.79 Million
1,180,124 New
1,180,124 $6.63 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $351M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Pier Capital, LLC Portfolio

Follow Pier Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier Capital, LLC with notifications on news.